Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis-Reference-Cited by-同舟云学术

Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis

Published:2020-02-12 Issue:2 Volume:15 Page:e0229028
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Aungsumart Saharat^ORCID,Apiwattanakul Metha

Funder

Prasat Neurological Institute, Department of Medical Services, Ministry of Public Health, Thailand.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference33 articles.

1. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis;VA Lennon;Lancet,2004

2. The spectrum of neuromyelitis optica;DM Wingerchuk;Lancet Neurol,2007

3. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange;H Abboud;Mult Scler,2016

4. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature;S Aungsumart;Mult Scler Relat Disord,2017

5. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders;M Bonnan;J Neurol Neurosurg Psychiatry,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the United Kingdom (UK) medicines pricing policy failing patients? The impact of terminated National Institute for Health and Care Excellence (NICE) appraisals for multi-indication products on patients;2024-08-07

2. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder;Scientific Reports;2024-02-12

3. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study;Immunological Medicine;2024-01-18

4. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-17

5. Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data;International Immunopharmacology;2022-09